ArticleJPGN reports2026
Muscular and serosal eosinophilic gastritis and enteritis with eosinophilic ascites successfully treated with dupilumab.
Article in JPGN reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary eosinophilic gastrointestinal disorders beyond the esophagus (EGIDs) are rare, predominantly Th2-mediated inflammatory conditions, affecting various segments of the gastrointestinal tract. We report the case of a 12-year-old boy with recurrent abdominal pain, peripheral eosinophilia, and progressive gastritis, duodenitis, and enteritis with eosinophilic ascites. He was diagnosed with extensive EGID with muscular and serosal involvement. He was treated with oral corticosteroids and milk elimination diet, which provided temporary relief, but relapses prompted the addition of dupilumab, which achieved durable remission. To our knowledge, this is the first reported case demonstrating the effectiveness of this monoclonal antibody in EGIDs with serosal involvement and eosinophilic ascites. This case highlights the therapeutic potential of dupilumab in refractory EGID cases involving deeper gastrointestinal layers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.